Abacus Life to Announce Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
ORLANDO, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Abacus Life, Inc. ('Abacus' or the 'Company') (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announced it will release its fourth quarter 2024 financial results after the market closes on Thursday, March 27, 2025.
Abacus will hold a conference call to discuss the financial results at 5:00 pm Eastern Time on March 27, 2025. A live webcast of the conference call will be available on Abacus' investor relations website at ir.abacuslife.com. The dial-in number for the conference call is (877) 407-9716 (toll-free) or (201) 493-6779 (international). Please dial the number 10 minutes prior to the scheduled start time.
A webcast replay of the call will be available at ir.abacuslife.com for one year following the call.
About Abacus
Abacus is a pioneering global alternative asset manager and market maker specializing in uncorrelated financial products. The company leverages its proprietary, cutting-edge longevity data and actuarial technology to purchase life insurance policies from consumers seeking liquidity. This creates a high-return asset class uncorrelated to market fluctuations for institutional investors.
With nearly $3 billion in assets under management, including recently completed acquisitions, Abacus is the only publicly traded global alternative asset manager focused on lifespan-based financial products.
Abacus is expanding its leading expertise in longevity and lifespan into new growth areas:
ABL Wealth - Leverages decades of data and proprietary algorithms to offer longevity-based wealth management platforms that enable financial advisors to create customized plans and provide access to uncorrelated investments.
ABL Tech - A groundbreaking technology service that delivers advanced real-time data tracking and analysis for pension funds, governments, insurance companies, retirement associations, and more.
Through each new channel, Abacus is revolutionizing the future of asset management and financial planning, centered on longevity and lifespan.
www.Abacuslife.com
Contact:
Investor Relations
Robert F. Phillips – SVP Investor Relations and Corporate Affairsrob@abacuslife.com(321) 290-1198
David Jackson – IR/Capital Markets Associatedjackson@abacuslife.com(321) 299-0716
Abacus Life Public Relationspress@abacuslife.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Sezzle Files Antitrust Action Against Shopify
Minneapolis, MN, June 09, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, announced today that it has filed a lawsuit against Shopify Inc. in the U.S. District Court for the District of Minnesota asserting federal and state antitrust violations. The lawsuit alleges that Shopify has been engaging and continues to engage in monopolistic and anticompetitive business practices in order to stifle competition for 'buy now, pay later' service options on Shopify's e-commerce platform. Sezzle is seeking an injunction to prevent Shopify from continuing its anticompetitive conduct that limits consumer choice and stifles fair market competition. The suit filed by the Company seeks treble damages. 'Sezzle remains committed to fostering a competitive, transparent, and consumer-friendly payments ecosystem,' stated Charlie Youakim, Sezzle Chairman and CEO. 'This action is an important step in ensuring that merchants and consumers have access to diverse and innovative payment solutions of their choice.' The Company also shared the following business updates: For the first quarter of 2025, revenue associated with gross merchandise volume attributable to Shopify's e-commerce platform represented less than 5.0% of Sezzle's total revenue. The Company is reaffirming its fiscal 2025 guidance, which was provided in its 1Q25 earnings release on May 7, 2025. Contact Information Lee Brading, CFA Investor Relations +1 651 240 6001 InvestorRelations@ Erin Foran Media Enquiries +1 651 403 2184 About Sezzle Inc. Sezzle is a forward-thinking fintech company committed to financially empowering the next generation. Through its purpose-driven payment platform, Sezzle enhances consumers' purchasing power by offering access to point-of-sale financing options and digital payment services—connecting millions of customers with its global network of merchants. Centered on transparency, inclusivity, and ease of use, Sezzle empowers consumers to manage spending responsibly, take charge of their finances, and achieve lasting financial independence. For more information visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations, whether stated or implied, regarding our financing plans and other future events. Forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," other words or expressions of similar meaning (or the negative versions of such words or expressions). These forward-looking statements address various matters including statements regarding the timing or nature of future operating or financial performance or other events. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: impact of the 'buy-now, pay-later' ('BNPL') industry becoming subject to increased regulatory scrutiny; impact of operating in a highly competitive industry; impact of macro-economic conditions on consumer spending; our ability to increase our merchant network, our base of consumers and gross merchandise value (GMV); our ability to effectively manage growth, sustain our growth rate and maintain our market share; our ability to maintain adequate access to capital in order to meet the capital requirements of our business; impact of exposure to consumer bad debts and insolvency of merchants; impact of the integration, support and prominent presentation of our platform by our merchants; impact of any data security breaches, cyberattacks, employee or other internal misconduct, malware, phishing or ransomware, physical security breaches, natural disasters, or similar disruptions; impact of key vendors or merchants failing to comply with legal or regulatory requirements or to provide various services that are important to our operations; impact of the loss of key partners and merchant relationships; impact of exchange rate fluctuations in the international markets in which we operate; our ability to protect our intellectual property rights and third party allegations of the misappropriation of intellectual property rights; our ability to retain employees and recruit additional employees; impact of the costs of complying with various laws and regulations applicable to the BNPL industry in the United States and Canada; and our ability to achieve our public benefit purpose and our election to forego our B Corporation certification and other factors identified in the 'Risk Factors' section of our Annual Report on Form 10-K for the year ended December 31, 2025 (the 'Annual Report') and the Company's subsequent filings filed with the SEC. You are encouraged to read the Company's Annual Report and other filings with the SEC, available at for a discussion of these and other risks and uncertainties.. The Company cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. You are The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. The Company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. CONTACT: Erin Foran Sezzle 6514032184 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM. To access the video conference, please register online using this registration link. The presentation and conference details will also be available under 'Events & Presentations' in the Investors section of the Roivant website at The archived webcast will be available on Roivant's website after the conference call. About Priovant Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib is able to distinctively suppress key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with a single, targeted therapy. Brepocitinib is administered as a once-daily oral therapy. It has been dosed in over 1,400 subjects and has generated positive data in seven Phase 2 studies. Brepocitinib is currently being evaluated in dermatomyositis (Phase 3), non-infectious uveitis (Phase 3), and cutaneous sarcoidosis (Phase 2). About Roivant Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit Roivant Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are usually identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts:InvestorsKeyur MediaStephanie ResearchDaniel Herz-Roiphe
Yahoo
an hour ago
- Yahoo
Casey's Tops Estimates, Boosts Dividend
Casey's General Stores posted 11% revenue and 12% earnings-per-share growth in the quarter, surpassing Wall Street estimates. The company's results were aided by the acquisition of Fikes Wholesale, but Casey's managed to post inside same-store sales growth despite a tough operating environment. Casey's boosted its quarterly dividend for the 26th consecutive year and provided an initial forecast for growth in its new fiscal year. 10 stocks we like better than Casey's General Stores › Here's our initial take on Casey's General Stores' (NASDAQ: CASY) financial report. Metric Q4 FY24 Q4 FY25 Change vs. Expectations Revenue $3.60 billion $3.99 billion 11% Beat Earnings per share $2.34 $2.63 12% Beat Inside same-store sales +5.6% +1.7% -390 bp n/a Gross margin 41.2% 41.2% n/c n/a Convenience store powerhouse Casey's General Stores capped off a strong fiscal 2025, reporting double-digit quarterly revenue and earnings growth that topped expectations. The company is holding up better than a lot of retailers in a tough environment, with growth being driven by strong results from its bakery and hot sandwich offerings and from nonalcoholic beverages. Inside same-store sales grew by just 1.7% in the quarter, but CEO Darren Rebelez said that the full-year 2.6% growth "outperformed the industry." Casey's is also doing a good job of keeping a handle on costs, reducing same-store labor hours for the 12th consecutive quarter. Overall inside margin held steady year over year, with a slight uptick in grocery margin offset by a slight decrease in prepared food margin. This was a year of growth for Casey's. The company grew its store count from 2,658 to 2,904 over the past year, including about 35 new builds, as well as through its $1.1 billion acquisition of Fikes Wholesale, Casey's largest deal to date. Casey's continues to return more cash to shareholders. The company raised its quarterly dividend by 14% to $0.57 per share, marking the 26th consecutive annual increase. Investors seemed to like what Casey's was serving. The company's stock was up more than 7% immediately following the earnings release but ahead of Tuesday morning's planned call with investors. This is the end of Casey's fiscal year, and the company provided its first outlook for what it expects in the 12 months ahead. Casey's is forecasting that inside same-store sales will grow by 2% to 5% in fiscal 2026 and that EBITDA will grow by 10% to 12%. Casey's expects to continue to grow, forecasting it will open at least 80 stores via a combination of new construction and acquisitions, continuing on its three-year plan to expand by about 500 stores. This is a company that has been able to successfully apply its winning formula to new locations through both organic growth and M&A. It is a tough market for retail right now, but Casey's remains a standout. Full earnings report Investor relations page Before you buy stock in Casey's General Stores, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casey's General Stores wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool recommends Casey's General Stores. The Motley Fool has a disclosure policy. Casey's Tops Estimates, Boosts Dividend was originally published by The Motley Fool Sign in to access your portfolio
